Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed a Form 8-K on February 9, 2012, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2011. This filing serves as a notification to investors and the market about the company's financial performance during the reported periods. The press release, furnished as Exhibit 99.1, contains the detailed financial results and potentially highlights operational achievements or strategic updates. Investors should refer to this press release for specific figures regarding revenue, net income/loss, and any forward-looking statements or significant events disclosed by Alnylam.
Key Highlights
- 1Alnylam Pharmaceuticals announced its Q4 and Full Year 2011 financial results on February 9, 2012.
- 2The company filed a Form 8-K to report these financial results.
- 3The detailed financial results are provided in a press release, furnished as Exhibit 99.1.
- 4This filing is important for investors tracking Alnylam's financial performance and operational status.
- 5The information provided is for the period ending December 31, 2011.
- 6The filing does not contain extensive new operational disclosures beyond the financial results announcement.
Frequently Asked Questions
The main purpose of this Form 8-K filing is to announce Alnylam Pharmaceuticals' financial results for the fourth quarter and the full year ended December 31, 2011, to the public and investors.
The detailed financial results are presented in the press release dated February 9, 2012, which is furnished as Exhibit 99.1 to this Form 8-K filing.
This specific Form 8-K filing primarily focuses on the announcement of financial results. While the accompanying press release (Exhibit 99.1) may contain some operational commentary, it is not a dedicated filing for major strategic shifts or clinical trial updates. Investors should review the press release for any incidental mentions.
The disclaimer means that the information provided in this Form 8-K (specifically the press release) is being furnished to the SEC, not formally 'filed' under certain sections of the Securities Exchange Act of 1934 (like Section 18). This typically limits the liability associated with forward-looking statements within that furnished information, although it can still be incorporated by reference into other filings if explicitly stated.